Synairgen PLC (SYGGF) Stock Price, Trades & News

Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	14-Day RSI	92.78
	6-1 Month Momentum %	900

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History

GF Value Rank

	Name	Current	Vs Industry		Vs History
	EV-to-Forward-EBIT	-0.01
	EV-to-Forward-EBITDA	-0.01

GF Value™

SYGGF

Warning Signs

Warning! GuruFocus detected issues with SYGGF. Try a 7-Day Free Trial to check it out.

Synairgen PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Synairgen PLC Stock Events

Financials Calendars

Event	Date	Price ($)
General meeting for 2025	2025-10-10 14:00	0.00 (+0.00%)
Second quarter earnings results for 2025	2025-09-26	0.00 (+0.00%)
Annual report for 2024	2025-07-21	0.00 (+0.00%)
Fourth quarter earnings results for 2024	2025-07-14	0.00 (+0.00%)
Annual report for 2024	2025-06-27	0.00 (+0.00%)
Fourth quarter earnings results for 2024	2025-06-27	0.00 (+0.00%)
General meeting for 2024	2024-10-10 14:00	0.03 (+0.00%)
Second quarter earnings results for 2024	2024-09-26	0.04 (+0.00%)

Show

Entries

Guru Commentaries on OTCPK:SYGGF

No articles.

Press Release

	Subject	Date
	Synairgen Presents Detailed Analysis of Phase 3 SPRINTER Trial Evaluating SNG001 in Hospitalised COVID-19 Patients at ATS 2022	2022-05-16
	Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference	2022-04-05
	Synairgen announces global strategic partnership with Ashfield Engage	2022-01-06
	Synairgen Presents In Vitro Potency Data for Interferon Beta Against SARS-CoV-2 Variants and Lung Antiviral Biomarker Data for Inhaled SNG001 at the 8th ESWI Influenza Conference	2021-12-07
	Synairgen completes recruitment in its international Phase 3 SPRINTER study of SNG001 in hospitalised COVID-19 patients	2021-11-11

10/Page

Articles on Synairgen PLC

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.